相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships
Jamshid S. Khorashad et al.
BLOOD (2013)
Effects of the Hedgehog Inhibitor GDC-0449, Alone or in Combination with Dasatinib, on BCR-ABL-Positive Leukemia Cells
Seiichi Okabe et al.
STEM CELLS AND DEVELOPMENT (2012)
Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells
Faiyaz Notta et al.
NATURE (2011)
First-line therapy for chronic myeloid leukemia: past, present, and future
Carolina Pavlovsky et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up
Ravin J. Garg et al.
BLOOD (2009)
Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
Douglas W. McMillin et al.
CANCER RESEARCH (2009)
PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer
Robert J. Crowder et al.
CANCER RESEARCH (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
Ta-Jen Liu et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
Anthony C. Faber et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature:: Implications for clinical imaging
Christian R. Schnell et al.
CANCER RESEARCH (2008)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra et al.
CANCER RESEARCH (2008)
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
Jaclyn LoPiccolo et al.
DRUG RESISTANCE UPDATES (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML
K. Kojima et al.
LEUKEMIA (2008)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia
C. Sillaber et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2008)
Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study
Arghya Ray et al.
BLOOD (2007)
Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis
Seiichi Okabe et al.
STEM CELLS AND DEVELOPMENT (2007)
Physiological roles of PKB/Akt isoforms in development and disease
B. Dummler et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2007)
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance
Hagop M. Kantarjian et al.
ANNALS OF INTERNAL MEDICINE (2006)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia
S Kimura et al.
BLOOD (2005)
Advances in protein kinase B signalling:: AKTion on multiple fronts
DP Brazil et al.
TRENDS IN BIOCHEMICAL SCIENCES (2004)
Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy
A Hochhaus et al.
LEUKEMIA (2002)
Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571
A Klejman et al.
ONCOGENE (2002)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
M Hidalgo et al.
ONCOGENE (2000)
分享论文
